Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 3/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11085445 | 0.98 | ZDHHC20 (0.47) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 | |
| SCHEMBL2159389 | 0.83 | ZDHHC20 (0.46) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 | |
| SCHEMBL2159395 | 0.83 | ZDHHC20 (0.46) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 | |
| SCHEMBL2362353 | 0.83 | ZDHHC20 (0.46) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 | |
| SCHEMBL293960 | 0.82 | CA12 (0.48) | ZDHHC20ZDHHC2FAAHCA12CA1 | |
| SCHEMBL7596175 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TSHRMEN1KMT2ADPP4 | |
| SCHEMBL6252070 | 0.81 | GRIN2D (0.41) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 | |
| SCHEMBL3259264 | 0.81 | ZDHHC20 (0.45) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 | |
| SCHEMBL1076719 | 0.81 | ZDHHC20 (0.61) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 | |
| SCHEMBL8033183 | 0.81 | ALDH1A1 (0.47) | ZDHHC20ZDHHC2ALDH1A1FAAHCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026273-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | claimed |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-18 | — | — | US | claimed |
| EP-4157242-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Galera Labs, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | claimed |
| WO-2023009500-A1 | PENTAAZA MACROCYCLIC RING COMPLEX FOR ENHANCED SURGICAL TREATMENT | GALERA LABS, LLC (US) | 2023-02-02 | — | — | WO | claimed |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | GALERA LABS, LLC | 2022-07-21 | — | — | US | claimed |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | BIOSSIL INC. (CA) | 2022-04-21 | — | — | US | claimed |
| US-20210361701-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES FOR LOCAL DELIVERY | GALERA LABS, LLC | 2021-11-25 | — | — | US | claimed |
| EP-0679155-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. | MONSANTO CO (US) | 1995-11-02 | — | — | EP | claimed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0298742-B1 | Latent cure accelerators for cyanate esters | AMOCO CORP (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | claimed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | claimed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | claimed |
| US-4931496-A | Damage tolerant fiber-reinforced composites based on cyanate ester/urea thermosetting composition | AMOCO CORPORATION (US) | 1990-06-05 | — | — | US | claimed |
| US-4918157-A | COATINGS, ADHESIVES; STORAGE STABLE | AMOCO CORPORATION (US) | 1990-04-17 | — | — | US | claimed |
| US-4804740-A | STORAGE STABILITY | AMOCO CORPORATION (US) | 1989-02-14 | — | — | US | claimed |
| EP-0298742-A2 | Latent cure accelerators for cyanate esters | AMOCO CORPORATION (US) | 1989-01-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361701-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES FOR LOCAL DELIVERY | SI, APC, VIP | ZDHHC20 3969/4885ZDHHC2 3443/4885ALDH1A1 2560/4885 |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | MC2R, GHRHR, GNRHR | ZDHHC20 4029/4885ZDHHC2 3676/4885ALDH1A1 1209/4885 |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | HDAC1, HDAC8, SIRT3 | ZDHHC20 3443/4885ZDHHC2 2160/4885ALDH1A1 176/4885 |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | SOD1, MSH6, SLC30A6 | ZDHHC20 2422/4885ZDHHC2 3559/4885ALDH1A1 4478/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ZDHHC20 2877/4885ZDHHC2 3396/4885ALDH1A1 664/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | ZDHHC20 2877/4885ZDHHC2 3396/4885ALDH1A1 664/4885 |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | ZDHHC20 2673/4885ZDHHC2 1685/4885ALDH1A1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.